GLP-1 Drugs Revolutionize Prescriptions and Broader Health Applications
Once primarily for diabetes, GLP-1 drugs now account for 5% of U.S. prescriptions, with potential uses ranging from weight loss to treating Alzheimer’s and addiction.
- GLP-1 drugs like Ozempic and Wegovy have surged in popularity, making up 5.4% of all U.S. prescriptions for adults as of September 2024, up from 3.5% in 2023.
- The drugs, initially developed for diabetes, are now widely used for weight loss due to their ability to suppress hunger, helping users lose significant body weight.
- Researchers are exploring broader applications, including potential treatments for Alzheimer's disease, addiction, sleep apnea, and even life extension benefits.
- The FDA recently declared the shortage of tirzepatide, the active ingredient in Eli Lilly’s Zepbound, resolved, which could further expand access to these medications.
- High costs and limited insurance coverage remain barriers, with nearly half of new weight-loss prescriptions going unfilled despite growing demand.
MIT Technology Review 
The Street 
The Conversation 